SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Saxena, Neetu ^a   Maio, Nunziata ^a   Crooks, Daniel R ^b   Ricketts, Christopher J ^b   Yang, Youfeng ^b   Wei, Ming Hui ^b   Fan, Teresa W M ^c   Lane, Andrew N ^c   Sourbier, Carole ^b   Singh, Anamika ^a   Killian, J Keith ^b   Meltzer, Paul S ^b   Vocke, Cathy D ^b   Rouault, Tracey A ^a   Linehan, W Marston ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYSTEINE; DNA; GLUTAMINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON SULFUR PROTEIN; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUCCINIC ACID; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CHAPERONE; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HSCB PROTEIN, HUMAN; SDHB PROTEIN, HUMAN;

ARTICLE; BREATHING; CARCINOMA CELL; CITRIC ACID CYCLE; CONTROLLED STUDY; CPG ISLAND; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METABOLIC PARAMETERS; METABOLITE; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; DEFICIENCY; DNA METHYLATION; GENETICS; GERMLINE MUTATION; KIDNEY TUMOR; METABOLISM; MUTATION; POINT MUTATION; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GERM-LINE MUTATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON-SULFUR PROTEINS; KIDNEY NEOPLASMS; MOLECULAR CHAPERONES; MUTATION; MUTATION, MISSENSE; PHENOTYPE; POINT MUTATION; SUCCINATE DEHYDROGENASE;

EID: 84956575209     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv287     Document Type: Article

References (43)

1. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
2. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest. 2013;123(9):3652-3658.
3. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481:385-388.
4. Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 2011;20(3):315-327.
5. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology (Phila). 2012;44(4):285-292.
6. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74(1):153-159.
7. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100(17):1260-1262.
8. Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012;188(6):2063-2071.
9. Sun F, Huo X, Zhai Y, et al. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell. 2005;121(7):1043-1057.
10. Maio N, Singh A, Uhrigshardt H, Saxena N, Tong WH, Rouault TA. Cochaperone Binding to LYR Motifs Confers Specificity of Iron Sulfur Cluster Delivery. Cell Metab. 2014;19(3):445-457.
11. Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648-657.
12. Letouze E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23(6):739-752.
13. The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma. Nature. 2013;499(7456):43-49.
14. Yang Y, Valera VA, Padilla-Nash HM, et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet. 2010;196(1):45-55.
15. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77-85.
16. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
17. Baysal BE. Clinical and molecular progress in hereditary paraganglioma. J Med Genet. 2008;45(11):689-694.
18. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011-3020.
19. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108(1):314-318.
20. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat. 2011;32(5):557-563.
21. Celestino R, Lima J, Faustino A, et al. A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Fam Cancer. 2012;11(2):189-194.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
23. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us Cell. 2012;148(6):1132-1144.
24. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med (Berl). 2011;89(3):213-220.
25. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406-410.
26. Richter S, Peitzsch M, Rapizzi E, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab. 2014;99(10):3903-3911.
27. Lendvai N, Pawlosky R, Bullova P, et al. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology. 2014;155(1):27-32.
28. Piruat JI, Millan-Ucles A. Genetically modeled mice with mutations in mitochondrial metabolic enzymes for the study of cancer. Front Oncol. 2014;4:200.
29. Killian JK, Miettinen M, Walker RL, et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med. 2014;6(268):268ra177.
30. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943-951.
31. Lima J, Feijao T, Ferreira da SA, et al. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab. 2007;92(12):4853-4864.
32. Cascon A, Inglada-Perez L, Comino-Mendez I, et al. Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocr Relat Cancer. 2013;20(3):L1-L6.
33. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827-836.
34. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotypephenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41-51.
35. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817-2827.
36. Goffrini P, Ercolino T, Panizza E, et al. Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Hum Mol Genet. 2009;18(10):1860-1868.
37. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505-4509.
38. Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69(8):3650-3656.
39. Schiavi F, Savvoukidis T, Trabalzini F, et al. Paraganglioma syndrome: SDHB, SDHC, and SDHD mutations in head and neck paragangliomas. Ann N Y Acad Sci. 2006;1073:190-197.
40. Cascon A, Lopez-Jimenez E, Landa I, et al. Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res. 2009;41(9):672-675.
41. Korpershoek E, Petri BJ, van Nederveen FH, et al. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer. 2007;14(2):453-462.
42. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822-3828.
43. Bayley JP, Devilee P, Taschner PE. The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet. 2005;6:39.